KIORA PHARMACEUTICALS INC (KPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.66-4.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KPRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
KPRX — dividend update
Dated 2026-04-07
Entry Into a Material Definitive Agreement. Private Placement On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per s…
Why it matters: Kiora targets a Phase 3 start in 2027, but says funding and regulator talks can affect the plan. A clear path would support this new program.
Supportive ifKiora reports regulator alignment, a set trial design, and enough funding to start the CRAO Phase 3 in 2027.
Worry ifKiora delays the trial start beyond 2027, reports no funding path, or cannot agree on the trial plan with regulators.
Why it matters: The trial tests KIO-301 in late-stage retinitis pigmentosa. Kiora set topline data for Q3 2027, while a safety check must clear before more patients enroll.
Watch forKiora says the safety review is clear and enrollment is moving ahead. Topline data are due in Q3 2027, with a clear benefit on the trial's main vision measure.
Also watch forThe safety review stops or delays enrollment, or Q3 2027 data miss the main vision measure.
Why it matters: Kiora reported $16.8 million in cash and investments in Q2 and said it is seeking funds for KIO-401. The trial plan depends on funding.
Worry ifKiora reports no new funds, and its next update lowers the stated runway from late 2028.
Less concerning ifKiora secures enough new capital for the planned KIO-401 trials and keeps its stated runway at late 2028 or later.
Why it matters: Kiora's next earnings date is November 6. An update on trial timing, regulator talks, or funding can show whether the 2027 plan still holds.
Watch forAt the November 6 update, Kiora confirms a 2027 Phase 3 start. It shares progress on regulator talks and names a funding path.
Also watch forKiora moves the target start past 2027, reports a funding shortfall, or gives no update on the trial plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$152 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $463 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,545 loss on $10,000 · 45.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.